LBRX.US LB Pharmaceuticals Inc Common Stock

Healthcare Pharmaceuticals USA Stocks
43.01 USD
Close of Nov 15, 2026
15.19 50.16
Market cap
USD 1.39B
P/E
-
P/B
3.33x
ROE
-41.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LBRX.US undervalued?

Graham number

The Graham number of LB Pharmaceuticals Inc Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LB Pharmaceuticals Inc Common Stock fundamental analysis

No fundamental analysis for LB Pharmaceuticals Inc Common Stock yet.

LB Pharmaceuticals Inc Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formula…

Full company profile